 |
BioWorld-International-2004-02-25
InDex Signs $35M Agreement With Serono For Inflammation
InDex Signs $35M Agreement With Serono For Inflammation
InDex Pharmaceuticals AB signed its first product deal, out-licensing its antisense drug Kappaproct to Serono SA, of Geneva, for treatment of ulcerative colitis and other inflammatory conditions. (BioWorld International)